Original Research Online Published: 17 Jan 2023 | ||||||||||||
Randomized and parallel-group study of cost-effectiveness analysis of escitalopram and desvenlafaxine in moderate-to-severe depression Girish K, Moulya Nagaraj, Pavithra M S, Jyothi R, Lakshmi Pandith.
|
How to Cite this Article |
Pubmed Style K G, Nagaraj M, S PM, R J, Pandith L. Randomized and parallel-group study of cost-effectiveness analysis of escitalopram and desvenlafaxine in moderate-to-severe depression. Natl J Physiol Pharm Pharmacol. 2023; 13(2023, Vol: 13, Issue: 8): 1644-1649. doi:10.5455/njppp.2023.13.12618202209012022 Web Style K G, Nagaraj M, S PM, R J, Pandith L. Randomized and parallel-group study of cost-effectiveness analysis of escitalopram and desvenlafaxine in moderate-to-severe depression. https://www.njppp.com/?mno=134559 [Access: November 01, 2024]. doi:10.5455/njppp.2023.13.12618202209012022 AMA (American Medical Association) Style K G, Nagaraj M, S PM, R J, Pandith L. Randomized and parallel-group study of cost-effectiveness analysis of escitalopram and desvenlafaxine in moderate-to-severe depression. Natl J Physiol Pharm Pharmacol. 2023; 13(2023, Vol: 13, Issue: 8): 1644-1649. doi:10.5455/njppp.2023.13.12618202209012022 Vancouver/ICMJE Style K G, Nagaraj M, S PM, R J, Pandith L. Randomized and parallel-group study of cost-effectiveness analysis of escitalopram and desvenlafaxine in moderate-to-severe depression. Natl J Physiol Pharm Pharmacol. (2023), [cited November 01, 2024]; 13(2023, Vol: 13, Issue: 8): 1644-1649. doi:10.5455/njppp.2023.13.12618202209012022 Harvard Style K, G., Nagaraj, . M., S, . P. M., R, . J. & Pandith, . L. (2023) Randomized and parallel-group study of cost-effectiveness analysis of escitalopram and desvenlafaxine in moderate-to-severe depression. Natl J Physiol Pharm Pharmacol, 13 (2023, Vol: 13, Issue: 8), 1644-1649. doi:10.5455/njppp.2023.13.12618202209012022 Turabian Style K, Girish, Moulya Nagaraj, Pavithra M S, Jyothi R, and Lakshmi Pandith. 2023. Randomized and parallel-group study of cost-effectiveness analysis of escitalopram and desvenlafaxine in moderate-to-severe depression. National Journal of Physiology, Pharmacy and Pharmacology, 13 (2023, Vol: 13, Issue: 8), 1644-1649. doi:10.5455/njppp.2023.13.12618202209012022 Chicago Style K, Girish, Moulya Nagaraj, Pavithra M S, Jyothi R, and Lakshmi Pandith. "Randomized and parallel-group study of cost-effectiveness analysis of escitalopram and desvenlafaxine in moderate-to-severe depression." National Journal of Physiology, Pharmacy and Pharmacology 13 (2023), 1644-1649. doi:10.5455/njppp.2023.13.12618202209012022 MLA (The Modern Language Association) Style K, Girish, Moulya Nagaraj, Pavithra M S, Jyothi R, and Lakshmi Pandith. "Randomized and parallel-group study of cost-effectiveness analysis of escitalopram and desvenlafaxine in moderate-to-severe depression." National Journal of Physiology, Pharmacy and Pharmacology 13.2023, Vol: 13, Issue: 8 (2023), 1644-1649. Print. doi:10.5455/njppp.2023.13.12618202209012022 APA (American Psychological Association) Style K, G., Nagaraj, . M., S, . P. M., R, . J. & Pandith, . L. (2023) Randomized and parallel-group study of cost-effectiveness analysis of escitalopram and desvenlafaxine in moderate-to-severe depression. National Journal of Physiology, Pharmacy and Pharmacology, 13 (2023, Vol: 13, Issue: 8), 1644-1649. doi:10.5455/njppp.2023.13.12618202209012022 |